コンテンツへスキップ
Merck
  • Prevention of contrast nephropathy in critically ill patients using acetylcysteine and theophylline.

Prevention of contrast nephropathy in critically ill patients using acetylcysteine and theophylline.

The International journal of artificial organs (2005-01-14)
C Mueller
要旨

Compared with periprocedural hydration alone, acetylcysteine with hydration significantly reduces the risk of contrast nephropathy in patients with chronic renal insufficiency by 50%. For elective contrast procedures, acetylcysteine should be given in a dose of 600 mg twice daily the day before and on the procedure day. For emergency procedures, a high dose intravenous regimen (150 mg/kg in 500 mL normal saline over 30 minutes immediately before contrast followed by 50 mg/kg in 500 mL normal saline over 4h) is effective. Given the low cost and good side-effect profile of acetylcysteine, it would seem prudent to give this drug with intravenous fluids to all critically ill patients scheduled for intravenous or intraarterial contrast procedures. Theophylline in a dose of 200 mg or 2.5 mg/kg i.v. 30 minutes before contrast may be an effective alternative for emergency procedures. Although its benefit compared with periprocedural hydration alone seems less well established, theophylline is a particularly attractive option for emergency procedures.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
テオフィリン, anhydrous, ≥99%, powder
USP
テオフィリン, United States Pharmacopeia (USP) Reference Standard
Supelco
テオフィリン, Pharmaceutical Secondary Standard; Certified Reference Material
テオフィリン, European Pharmacopoeia (EP) Reference Standard